相关实验视频
Updated: Apr 30, 2026

05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
39.0K
用西尔德纳菲尔治疗抗抑郁药相关的性功能障碍:一个随机对照试验
H George Nurnberg1, Paula L Hensley, Alan J Gelenberg
1Department of Psychiatry, Health Sciences Center,University of New Mexico School of Medicine, 2400 Tucker NE, Albuquerque, NM 87131-5288, USA. geon@unm.edu
JAMA
|December 31, 2002
概括
西尔德纳菲尔有效治疗男性抗抑郁药诱导的性功能障碍. 这种改善性功能可能有助于患者坚持服用抗抑郁药物.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
- 性医学性医学性医学性医学
背景情况:
- 性功能障碍是抗抑郁药物的普遍副作用,往往导致患者停止治疗.
- 选择性和非选择性血清素再吸收抑制剂 (SRIs) 是常见的抗抑郁药,与性功能障碍相关.
研究的目的:
- 为了评估西尔德纳菲尔酸盐在治疗SRI抗抑郁药治疗的男性经历的性功能障碍方面的有效性.
- 为了确定西尔代纳菲尔是否可以改善受SRI抗抑郁药影响的性功能的各个领域.
主要方法:
- 一项随机,双盲,安慰剂对照试验,涉及90名男性门诊患者,患有缓解性严重抑郁症和SRI相关性性功能障碍.
- 参与者接受了西尔代纳菲尔 (灵活剂量50-100毫克) 或安慰剂六周,使用多个经过验证的尺度评估性功能.
主要成果:
- 与安慰剂相比,西尔德纳菲尔显著改善了勃起功能,兴奋,射精,高潮和整体性满意度 (P<.001).
- 超过54%的西尔代纳菲尔患者在性功能方面表现出显著的改善,而安慰剂组只有4.4%.
- 在整个研究期间,抑郁症症状严重程度在两组治疗群体中保持稳定和缓解.
结论:
- 西尔德纳菲尔是使用SRI抗抑郁药的男性性功能障碍的有效治疗方法.
- 用西尔德纳菲尔改善性功能可能会提高患者对必要抗抑郁药物治疗的坚持.
相关概念视频
Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379

